To Wall Street, psychedelics biotechs are more teammates than rivals

Definium's LSD Formulation Achieves "Best-Case" Results in Late-Stage Depression Trial

Definium Therapeutics announced positive late-stage trial data for its LSD formulation, demonstrating significant efficacy over placebo in relieving symptoms of major depression. This "best-case" scenario led to a nearly 50% jump in Definium's shares, trading around $37 apiece. Analysts, like Marc Goodman of Leerink Partners, raised peak sales estimates for the drug to $1.5 billion to $2 billion. Notably, the success did not negatively impact competitors like Compass Pathways, AtaiBeckley, and GH Research; instead, it was seen as validating the entire emerging psychedelics field, suggesting a "rising tide lifts all boats" effect for the sector.

• Definium Therapeutics reported "best-case" scenario results from its late-stage trial, where an LSD formulation significantly outperformed placebo in treating major depression. This strong efficacy led to a substantial increase in Definium's stock price, jumping nearly 50% to around $37 per share, reflecting strong investor confidence in the drug's potential.
• The positive trial data for Definium's LSD formulation prompted analysts, such as Marc Goodman of Leerink Partners, to significantly increase peak sales estimates for the drug, projecting figures between $1.5 billion and $2 billion. This financial outlook underscores the perceived commercial viability and market potential of psychedelic-based therapies for depression.
• Unlike traditional competitive drug markets, Definium's success was viewed as a positive for the entire psychedelics sector. Shares of rival companies like Compass Pathways and Helus Pharma remained stable or even rose, indicating that investors see individual successes as validating the emerging field as a whole, fostering a collaborative environment for infrastructure development and broader adoption.

Definium's LSD Shows Profound Efficacy in Major Depression

Three recent studies illustrate the breadth of approaches being evaluated in major depressive disorder (MDD), spanning novel pharmacology, neuromodulation, and structured psychotherapy. The GH001 Phase 2b Trial (2026) evaluated GH001 — a synthetic mebufotenin formulated for inhalation — administered via a single-day individualized dosing regimen in 40 patients with treatment-resistant depression (TRD). The intervention produced rapid and substantial antidepressant effects, with a least-squares mean difference versus placebo of −15.5 (effect size −2.0) on the MADRS. Remission at Day 8 was achieved by 57.5% of GH001-treated patients versus 0% on placebo, and remission rates were consistent across subgroups defined by number of prior antidepressant failures (range 53.9%–63.6%), with no meaningful correlation between prior treatment failures and MADRS improvement at Day 8 (r = −0.13; P = 0.44). Notably, remission was maintained through the 6-month open-label extension (range 61.5%–85.7%), and secondary endpoints were not associated with treatment history, suggesting GH001's efficacy is largely independent of prior treatment burden.

The CREST-MST Trial (2018–2024) was a multi-centre confirmatory efficacy and safety trial conducted across three academic centres in Canada and the USA, randomly assigning 239 patients to either magnetic seizure therapy (MST) using a twin coil in the midline frontal position or right unilateral ultra-brief electroconvulsive therapy (RUL-UB ECT). On the primary efficacy endpoint — remission on the Hamilton Rating Scale for Depression-24 item — MST demonstrated non-inferiority to RUL-UB ECT, with remission rates of 22.5% versus 27.8% respectively (difference 5.3% in favour of RUL-UB ECT; Z-test p = 0.048, 95% CI −4.4 to 14.9). The differentiation between modalities was most pronounced on the safety profile: autobiographical memory worsening was observed in 17.3% of RUL-UB ECT patients compared to only 2.7% in the MST group (p = 0.0003), and more participants in the ECT arm withdrew due to non-serious adverse events (n = 12 vs. n = 3).

The Toludesvenlafaxine Study (2026) was a single-arm, multicenter clinical study enrolling 61 patients who had demonstrated insufficient or partial response after four weeks of initial antidepressant therapy (MADRS ≥24). Patients were switched to toludesvenlafaxine, a triple reuptake inhibitor, for an 8-week treatment period. The primary outcome — change in MADRS score from baseline to week 8 — showed a mean reduction of 15.5 points (95% CI −17.7 to −13.3; p < 0.0001; Cohen's d = 2.35), with 43% achieving clinical remission and 67% meeting response criteria. Meaningful effects were evident as early as week 2 (Cohen's d = 1.52) and week 4 (Cohen's d = 2.11). Secondary outcomes including HAMA, Q-LES-Q-SF, CGI-S, and DARS scores all showed statistically significant improvement. From a safety standpoint, the most common adverse reactions were palpitations, constipation, nausea, vomiting, hypoesthesia, and dizziness, characterised as predominantly mild to moderate and manageable. Notably, the agent was also associated with a statistically significant improvement in sexual dysfunction (95% CI −4.3 to −0.7; p = 0.0071), a clinically meaningful differentiator relative to conventional antidepressant classes.

Addressing Unmet Needs in Major Depression with Psychedelics

Despite meaningful advances in antidepressant pharmacotherapy, substantial gaps in diagnosis, access, and treatment response persist across diverse global populations. Recent literature highlights a convergence of sociodemographic, geographic, and biological factors that continue to drive inequitable outcomes in major depression, underscoring the relevance of targeted, precision-oriented interventions — including emerging psychedelic-assisted approaches.

• Treatment-resistant depression (TRD) remains a critical unmet need, affecting approximately 30% of patients who fail to respond to standard antidepressants. In underserved and uninsured communities — where Nurse Practitioners frequently serve as the primary mental health providers — access to specialized TRD management is severely limited, compounding the challenge of this refractory population.

• Racial and ethnic minority groups face disproportionate treatment gaps. In Brazil, over 70% of depressed adults received no care, with Black and brown/mixed-race individuals significantly more likely to go untreated; 44.6% of this racial disparity in the treatment gap remained unexplained by observable differences, suggesting structural discrimination and access barriers as contributing drivers. Similarly, in U.S. data, Black adults showed lower odds of perceiving need (OR = 0.50) and accessing treatment (OR = 0.62), while Hispanic adults demonstrated comparable disparities.

• Socioeconomically vulnerable populations carry elevated depression burden with minimal care penetration. In Bangladesh, despite a weighted prevalence of 5.2% for depressive disorders, only 4.1% of affected individuals sought professional help. Higher prevalence was concentrated among the unemployed (aOR = 2.87), divorced/separated/widowed individuals (aOR = 2.09), those with lower educational attainment (aOR = 1.68), and individuals with a family history of mental illness (aOR = 3.58).

• Age-defined subgroups — particularly adolescents and the elderly — represent distinct underserved populations. Depression burden among the elderly in China increased significantly from 1990 to 2019, while COVID-19 reversed prior gains in anxiety burden among young adults. Adolescents, especially pregnant and parenting girls in Sub-Saharan Africa, face elevated peripartum depression risk with minimal access to preventive or therapeutic mental health services.

• Transgender individuals exhibit among the highest unmet need burdens documented. In India, 72% of transgender women with gender dysphoria met criteria for a DSM-5-TR mental disorder, with major depressive disorder as the most prevalent diagnosis (40%). Only 8.5% of identified needs were met, with unmet needs spanning psychological distress (44.5%), welfare benefits (69.5%), and basic education (40.1%).

• Culturally specific symptom presentations create diagnostic and screening gaps. In Bangladesh, somatic symptoms were reported more frequently than affective or cognitive symptoms of depression, highlighting the need for culturally adapted screening instruments and routine depression assessment in patients presenting with physical complaints — a gap with direct implications for study design and patient identification in clinical trials.

Evolving Major Depression Treatment Landscape and Market Dynamics

The treatment landscape for major depressive disorder (MDD) has undergone substantial diversification over the past five years, with pharmacological innovation moving well beyond conventional monoaminergic strategies. A landmark development has been the clinical emergence of toludesvenlafaxine (ansofaxine), the first-in-class triple monoaminergic reuptake inhibitor (TRI), which demonstrated the highest odds ratio for antidepressant response (OR 4.52; 95% CI: 2.65–7.72) in a network meta-analysis of 602 studies enrolling 135,180 participants. Rapid-acting mechanisms have also gained significant traction: GH001, a synthetic mebufotenin formulation for inhalation, produced an effect size of −2.0 versus placebo in a Phase 2b trial for treatment-resistant depression (TRD), with 57.5% remission at Day 8 versus 0% in the placebo arm — remission rates that were sustained through Month 6. Glutamatergic agents including intranasal esketamine have advanced through Phase 3 for TRD, while neuroactive steroids such as brexanolone and zuranolone have expanded the therapeutic toolkit for specific depressive subtypes. Augmentation strategies using second-generation antipsychotics have been further characterized, with network meta-analysis data (33 trials, 10,602 participants) identifying risperidone as the most efficacious agent for response (OR 2.17; 95% CrI 1.38–3.42), and positioning aripiprazole and risperidone as the most favorable in combined efficacy-acceptability profiles.

Neuromodulation and psychotherapeutic interventions have simultaneously accumulated a stronger evidence base. Bilateral repetitive transcranial magnetic stimulation (brTMS) demonstrated significantly superior outcomes versus sham for both response (RR 2.69; 95% CI 1.58–4.57) and remission (RR 3.84; 95% CI 1.62–9.07), with mechanistic data implicating dopamine system modulation and grey matter volumetric changes in the frontal-limbic network as probable therapeutic substrates. Transcranial direct current stimulation (tDCS) showed meaningful short-term reduction in depressive symptoms in TRD (SMD: −1.17; 95% CI −1.85 to −0.49), though findings at 30-day follow-up were not significant and heterogeneity remains a limitation. On the psychotherapy front, cognitive behavioral therapy (CBT) combined with pharmacotherapy demonstrated domain-specific neurocognitive benefits over pharmacotherapy alone, including improvements in verbal memory (F[1,95] = 4.59, p = .035) and executive function (Cohen's d = 0.442). Mindfulness-based cognitive therapy (MBCT) showed efficacy in reducing suicidal ideation and serum IL-6 levels in adolescent populations, suggesting immunomodulatory effects alongside symptomatic benefit. A five-year longitudinal follow-up study further reinforced the durability of psychotherapy outcomes, with patients receiving psychological treatment demonstrating somewhat superior long-term symptom trajectories compared to those on pharmacotherapy, even after adjusting for baseline severity and personality pathology.

At the research and regulatory frontier, an analysis of 10,606 depression trials registered in the ICTRP identified 663 unique investigational agents, with ketamine, sertraline, duloxetine, and fluoxetine among the most studied. Twenty-six novel investigational antidepressants targeting 16 distinct drug targets are currently in active development, including kappa-opioid receptor antagonists, orexin-2 antagonists (seltorexant), GABA modulators, and psychedelic-assisted pharmacotherapies. Pharmacogenomic data from the Australian Genetics of Depression Study (n = 12,074) have begun to characterize the genetic architecture of antidepressant treatment complexity, identifying immune-related loci such as SLAMF3/LY9 (rs4656934; OR = 0.81 for sustained SSRI use) and polygenic score associations with psychiatric comorbidities that may eventually inform precision prescribing. Concurrently, dosing optimization analyses across 21 antidepressants suggest that maximal efficacy is typically achieved at low-to-middle dose ranges — with agomelatine and escitalopram exhibiting the most favorable efficacy-tolerability balance — while no antidepressant demonstrated a net benefit in patients over 70 years due to adverse event burden exceeding clinical gain.